India, Aug. 13 -- C4 Therapeutics, Inc. (CCCC), a clinical-stage biotech company, released second-quarter results, with its net loss narrowing due to revenue from a collaboration agreement.
Company Profile
The company is focused on developing targeted protein degraders (TPDs) to treat cancer and other diseases. Its lead program, cemsidomide, is an oral IKZF1/3 degrader being developed for multiple myeloma. The pipeline also includes CFT8919, an EGFR L858R degrader for non-small cell lung cancer, while discovery programs target inflammation, neuroinflammation and neurodegenerative diseases.
Second Quarter Financial Highlights
For the second quarter, net loss narrowed to $23.63 million, or $0.18 per share, from $26.02 million, or $0.37 pe...